Patent ID: 11883375
Assignee: SPRINGWORKS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein
(I) an amount of mirdametinib is administered on the first day of treatment to provide an AUC0-tau less than 300 ng·h/mL; and
(II) (a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib,
(b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib, or
(c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib.